Subchronic administration of clozapine, but not haloperidol or metoclopramide, decreases dopamine D2 receptor messenger RNA levels in the nucleus accumbens and caudate-putamen in rats

Neuroscience

Volumn 72, Issue 1, 1996, Pages 99-104

  See, R E ^a   Lynch, A M ^a   Sorg, B A ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

caudate putamen; clozapine; dopamine; haloperidol; metoclopramide; nucleus accumbens

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; MESSENGER RNA; METOCLOPRAMIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; MALE; NONHUMAN; NORTHERN BLOTTING; NUCLEUS ACCUMBENS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PUTAMEN; RAT; RECEPTOR BINDING;

EID: 0029881406     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-4522(95)00540-4     Document Type: Article

References (45)

1. Adams M. R., Malouf A., Unis A. and Dorsa D. M. (1994) Signal transduction effects of antipsychotic drugs in vivo and in organotypic cultures of rat brain striatum. Soc. Neurosci. Abst. 20, 523.
2. Altar C. A., Boyar W. C., Wasley A., Gerhardt S. C., Liebman J. M. and Wood P. L. (1988) Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists Naunyn Schmiedeberg's Arch. Pharmac. 338, 162-168.
3. Anden N. E. and Stock G. (1973) Effects of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J. Pharm. Pharmac. 25, 346-348.
4. Angulo J. A., Coirini H., Ledoux M. and Schumacher M. (1991) Regulation by dopaminergic neurotransmission of dopamine D2 mRNA and receptor levels in the striatum and nucleus accumbens of the rat. Molec. Brain Res. 11, 161-166.
5. Bartholini G. (1977) Preferential effect of noncataleptogenic neuroleptics on mesolimbic dopaminergic function. In Advances in Biochemical Psychopharmacology (eds Costa E. and Gessa G. L.), pp. 607-611. Raven Press, New York.
6. Bernard V., Le Moine C. and Bloch B. (1991) Striatal neurons express increased levels of dopamine D2 receptor mRNA in response to haloperidol treatment: a quantitative in situ hybridization study. Neuroscience 45, 117-126.
7. 1 affect synapsis-dependent genetic behavior of white and transcriptional regulatory mutations. Cell 40, 819-823.
8. Buckland P. R., O'Donovan M. C. and McGuffin P. (1992) Changes in dopamine D1, D2 and D3 receptor mRNA levels in rat brain following antipsychotic treatment. Psychopharmacology 106, 479-483.
9. Bunzow J. R., Van Tol H. H. M., Grandy D. K., Albert P., Salon J., Christie M., Machida C. A., Neve K. A. and Civelli O. (1988) Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336, 783-787.
10. Casey D. E. (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99, 47-53.
11. Civelli O., Bunzow J. R. and Grandy D. K. (1993) Molecular diversity of the dopamine receptors. A. Rev. Pharmac. Toxicol. 32, 281-307.
12. Coirini H., Schumacher M., Angulo J. A. and McEwen B. S. (1990) Increase in striatal dopamine D2 receptor mRNA after lesions of haloperidol treatment. Eur. J. Pharmac. 186, 369-371.
13. Criswell H. E., Mueller R. A. and Breese G. A. (1989) Clozapine antagonism of D-1 and D-2 dopamine receptor-mediated behaviors. Eur. J. Pharmac. 159, 141-147.
14. Deutch A. Y. (1994) Identification of the neural systems subserving the actions of clozapine: clues from immediate-early gene expression. J. clin. Psychiat. 55(9, suppl B), 37-42.
15. Farde L., Nordstrom A. L., Wiesel F. A., Pauli S., Halldin C. and Sedvall G. (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. gen. Psychiat. 49, 538-544.
16. Giardino L., Calza L., Piazza P. V. and Amato G. (1991) Multiple neurochemical action of clozapine: a quantitative autoradiographic study of DA 2, opiate and benzodiazepine receptors in the rat brain after long-term treatment. J. neural Trans. 83, 189-203.
17. Hitri A., Weiner W. J., Borison R. L., Diamond B. I., Nausieda P. A. and Klawans H. L. (1978) Dopamine binding following prolonged haloperidol pretreatment. Ann. Neurol. 3, 134-140.
18. LaHoste G. J. and Marshall J. F. (1989) Non-additivity of D2 receptor proliferation induced by dopamine denervation and chronic selective antagonist administration: evidence from quantitative autoradiography indicates a single mechanism of action. Brain Res. 502, 223-232.
19. Laruelle M., Jaskiw G. E., Lipska B. K., Kolachana B., Casanova M. F., Kleinman J. E. and Weinberger D. R. (1992) D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment. Brain Res. 575, 47-56.
20. Lowry O. H., Rosebrough N. J., Farr A. L. and Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. biol. Chem. 193, 265-275.
21. Marsden C. D. and Jenner P. (1980) The pathophysiological basis of extrapyramidal movement disorders. Psychol. Med. 10, 55-71.
22. Matsunaga T., Ohara K., Natsukari N. and Fujita M. (1991) Dopamine D2-receptor mRNA level in rat striatum after chronic haloperidol treatment. Neurosci. Res. 12, 440-445.
23. Meltzer H. Y. (1989) Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99, 18-27.
24. Meltzer H. Y. (1994) An overview of the mechanism of action of clozapine. J. clin. Psychiat. 55(9, Suppl B), 47-52.
25. Miller L. G. and Jankovic J. (1989) Metoclopramide induced movement disorders. Clinical findings with a review of the literature. Arch. intern. Med. 149, 2486-2492.
26. Nordstrom A., Farde L., Wiesel F., Forslund K., Pauli S., Halldin C. and Uppfeldt G. (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a doubleblind PET study of schizophrenic patients. Biol. Psychiat. 33, 227-235.
27. Nudel V., Zakut R., Shani M., Neuman S., Levy Z. and Yaffe D. (1983) The nucleotide sequence of the rat cytoplasmic β-actin gene. Nucl. Acids Res. 11, 1759-1771.
28. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego.
29. 2 dopamine receptor reappearance after irreversible receptor blockade. Brain Res. 435, 147-152.
30. Prosser E. S., Pruthi R. and Csernansky J. G. (1989) Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride. Psychopharmacology 99, 109-116.
31. Rebec G. V., Bashore T. R., Zimmerman K. S. and Alloway K. D. (1980) Neostriatal and mesolimbic neurons: dose dependent effects of clozapine. Neuropharmacology 19, 281-288.
32. Rogue P., Hanauer A., Zwiller J., Malviya A. N. and Vincendon G. (1991) Up-regulation of dopamine D2 receptor mRNA in rat striatum by chronic neuroleptic treatment. Eur. J. Pharmac. molec. Pharmac. 207, 165-168.
33. Rogue P. and Malviya A. N. (1994) Neuroleptics differentially induce jun family genes in the rat striatum. Neuro Report 5, 501-503.
34. Rupniak N. M. J., Kilpatrick G., Hall M. D., Jenner P. and Marsden C. D. (1984) Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats. Psychopharmacology 84, 512-519.
35. Scherer J., Tatsch K., Schwarz J., Oertel W. H., Konjarczyk M. and Albus M. (1994) D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta psychiat. Scand. 90, 266-268.
36. A and dopamine D-2, but not dopamine D-1 receptors. Life Sci. 44, 229-236.
37. See R. E. and Chapman M. A. (1994) The consequences of long-term antipsychotic drug administration on basal ganglia neuronal function in laboratory animals. Crit. Rev. Neurobiol. 8, 85-124.
38. See R. E., Toga A. W. and Ellison G. D. (1990) Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats. J. neural Transm. 82, 93-109.
39. Seeger T. F., Thal L. and Gardner E. L. (1982) Behavioral and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: studies with chronic clozapine and haloperidol. Psychopharmacology 76, 182-187.
40. Seeman P. (1992) Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7, 261-284.
41. Srivastava L. K., Morency M. A., Bajwa S. B. and Mishra R. K. (1990) Effect of haloperidol on expression of dopamine D2 receptor mRNAs in rat brain. J. molec. Neurosci. 2, 155-161.
42. 2 dopamine mRNA level. Neurosci. Lett. 111, 303-308.
43. White F. J. and Wang R. Y. (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221, 1054-1057.
44. Xu S., Monsma F. J., Sibley D. R. and Creese I. (1992) Regulation of D1A and D2 dopamine receptor mRNA during ontogenesis, lesion and chronic antagonist treatment. Life Sci. 50, 383-396.
45. Zahm D. S. (1991) Compartments in rat dorsal and ventral striatum revealed following injection of 6-hydroxydopamine into the ventral mesencephalon. Brain Res. 552, 164-169.